Table 4.
Comparison of Clinicopathological Features Between Patients of Different Molecular Subtypes and Patients with NSMP, Respectively
| Clinicopathological Features | NSMP (n = 159) | dMMR | p53 Abnormal | POLE Mutant | |||
|---|---|---|---|---|---|---|---|
| dMMR (n = 197) | p values (dMMR vs NSMP) | p53 Abnormal (n = 155) | p values (p53 Abnormal vs NSMP) | POLE Mutant (n = 52) | p values (POLE Mutant vs NSMP) | ||
| Age (years) | |||||||
| <55, n (%) | 65(40.9%) | 76(38.6%) | 0.665 (χ2= 0.195) | 62(40.0%) | 0.909 (χ2= 0.025) | 20(38.5%) | 0.871 (χ2= 0.095) |
| ≥55, n (%) | 94(59.1%) | 121(61.4%) | 93(60.0%) | 32(61.5%) | |||
| Reproductive history | |||||||
| No, n (%) | 8(5.0%) | 5(2.5%) | 0.261 (χ2= 1.555) | 2(1.3%) | 0.104 (χ2= 3.563) | 1(1.9%) | 0.458 (χ2= 0.927) |
| Yes, n (%) | 151(95.0%) | 192(97.5%) | 153(98.7%) | 51(98.1%) | |||
| Menopause | |||||||
| No, n (%) | 55(34.6%) | 63(32.0%) | 0.651 (χ2= 0.237) | 43(27.7%) | 0.225 (χ2= 1.523) | 13(25.0%) | 0.236 (χ2= 1.461) |
| Yes, n (%) | 104(65.4%) | 133(67.5%) | 110(71.0%) | 38(73.1%) | |||
| Histological type | |||||||
| Endometrioid carcinoma, n (%) | 151(95.0%) | 180(91.4%) | 1.000 (χ2= 0.010) | 107(69.0%) | <0.001 (χ2= 32.242) | 45(86.5%) | 1.000 (χ2= 0.109) |
| Non-endometrioid carcinoma, n (%) | 8(5.0%) | 10(5.1%) | 44(28.4%) | 3(5.8%) | |||
| Tumor differentiation | |||||||
| Well, n (%) | 43(27.0%) | 43(21.8%) | 0.004 (χ2= 10.885) | 20(12.9%) | <0.001 (χ2= 23.005) | 12(23.1%) | 0.268 (χ2= 2.872) |
| Moderate, n (%) | 103(64.8%) | 107(54.3%) | 76(49.0%) | 27(51.9%) | |||
| Poor, n (%) | 9(5.7%) | 32(16.2%) | 32(20.6%) | 6(11.5%) | |||
| Muscular infiltration | |||||||
| Endometrium, n (%) | 25(15.7%) | 38(19.3%) | 0.477 (χ2= 1.530) | 16(10.3%) | 0.651 (χ2= 0.887) | 5(9.6%) | 0.744 (χ2= 0.627) |
| <1/2 muscular layer, n (%) | 97(61.0%) | 105(53.3%) | 83(53.5%) | 27(51.9%) | |||
| ≥1/2 muscular layer, n (%) | 29(18.2%) | 30(15.2%) | 27(17.4%) | 6(11.5%) | |||
| Lymphovascular invasion | |||||||
| Absent, n (%) | 125(78.6%) | 146(74.1%) | 0.867 (χ2= 0.101) | 104(67.1%) | 0.196 (χ2= 1.896) | 30(57.7%) | 0.442 (χ2= 0.613) |
| Present, n (%) | 20(12.6%) | 21(10.7%) | 26(16.8%) | 7(13.5%) | |||
| Perineural invasion | |||||||
| Absent, n (%) | 143(89.9%) | 166(84.3%) | 1.000 (χ2= 0.859) | 124(80.0%) | 0.466 (χ2= 1.148) | 36(69.2%) | 0.206 (χ2= 3.886) |
| Present, n (%) | 0(0) | 1(0.5%) | 1(0.6%) | 1(1.9%) | |||
| Disease stage | |||||||
| I-II, n (%) | 143(89.9%) | 158(80.2%) | 0.196 (χ2= 1.919) | 100(64.5%) | <0.001 (χ2= 13.591) | 40(76.9%) | 0.214 (χ2= 1.969) |
| III-IV, n (%) | 16(10.1%) | 28(14.2%) | 36(23.2%) | 3(5.8%) | |||
Abbreviations: dMMR, mismatch repair-deficient; POLE, DNA polymerase epsilon; NSMP, no specific molecular profile.